In this episode of "The Top Line," we talk with ViiV’s head of R&D, Dr. Kimberly Smith, about new HIV therapies. We also cover Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines.
To learn more about the topics in this episode:
- Explore the categories of the Fierce 50
- AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
- Boehringer Ingelheim launches first interchangeable biosimilar to AbbVie's Humira
- Moderna strikes deal worth up to $1B to develop, produce mRNA drugs in China: reports
- GSK's ViiV explores novel pathway to bring long-acting HIV med Cabenuva to tough-to-treat patients